The U.S. Food and Drug Administration is warning that certain half-shell oysters that are frozen and raw harvested in South ...

Authorities are investigating after several people came down with symptoms of norovirus, the highly-contagious, ...

Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against ...

The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled study. It is designed to evaluate the relative efficacy, safety, and immunogenicity of Vaxart's oral COVID-19 ...

Vaxart's oral norovirus vaccine shows promise in mid-stage trials, reducing infections by 30%. Read more here.

Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the appointme ...

An oral vaccine reduced infection risk in a trial where people were deliberately exposed to high doses of norovirus, and ...

Discover key insights from Vaxart's Q1 2025 earnings call, including progress on COVID-19 trials, norovirus pipeline updates, funding strategies, and ...

Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s ...

HilleVax reports Q1 2025 financials: $159.5 million in assets, reduced losses, and ongoing vaccine development for norovirus. HilleVax, Inc. announced its financial results for the first quarter ...

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation ...

Topline data is expected in mid-2025, marking a key milestone in the development of a needle-free, shelf-stable pill vaccine to address norovirus, a leading global cause of acute gastroenteritis.